PMID- 36605430
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Serum soluble DR5 predicts mortality risk in patients with HBV-related 
      hepatocellular carcinoma.
PG  - 1040812
LID - 10.3389/fonc.2022.1040812 [doi]
LID - 1040812
AB  - INTRODUCTION: Death receptor 5 (DR5) is significantly upregulated in various 
      human tumor tissues; however, the relationship between serum levels of soluble 
      DR5 (sDR5) and the mortality risk of hepatocellular carcinoma (HCC) is not 
      understood. Our aim is to investigate the prognostic value of serum sDR5 in HCC 
      patients. METHODS: A total of 170 patients with HBV-HCC were recruited, with 82 
      and 88 patients as derivation and validation cohorts, respectively. sDR5 levels 
      were analyzed using ELISA. The predictive factors for mortality were selected 
      using LASSO regression analysis. Cox regression analysis was used to analyze the 
      independent factors affecting mortality in 2 years. A nomogram based on the 
      interquartile range of the sDR5 values predicted mortality rates. RESULTS: Serum 
      sDR5 level was identified as an independent risk factor for mortality in patients 
      with HBV-HCC. The 2-year cumulative mortality rates of HBV-HCC were 10, 28.57, 
      38.10, and 95% across the sDR5 quartiles, respectively (p < 0.001). The sDR5 had 
      an AUROC of 0.851 (95% CI: 0.755-0.920) in the derivation cohort. When the 
      cut-off value was 30.06pg/mL, the AUROC of sDR5 was 0.778 (95% CI 0.677-0.860) in 
      the validation cohort. The calibration curves fit well, and the decision curves 
      showed that sDR5 had a high standardized net benefit. sDR5 predicted the 
      prognosis of HBV-HCC patients most accurately. Further, serum sDR5 level was 
      significantly positively associated with BCLC stage and the presence or absence 
      of ascites. CONCLUSION: sDR5 showed high predictive accuracy in patients with 
      HBV-HCC; thus, it is considered a new serological biomarker.
CI  - Copyright (c) 2022 Liang, Feng, Liu, Shi, Zhou, Liu, Liu, Qiao, Liu and Wang.
FAU - Liang, Jiaqi
AU  - Liang J
AD  - Department of Infectious Disease, Beijing Hospital of Traditional Chinese 
      Medicine, Capital Medical University, Beijing,  China.
FAU - Feng, Ying
AU  - Feng Y
AD  - Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical 
      University, Beijing,  China.
FAU - Liu, Yao
AU  - Liu Y
AD  - Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical 
      University, Beijing,  China.
FAU - Shi, Ke
AU  - Shi K
AD  - Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical 
      University, Beijing,  China.
FAU - Zhou, Guiqin
AU  - Zhou G
AD  - Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical 
      University, Beijing,  China.
FAU - Liu, Long
AU  - Liu L
AD  - Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical 
      University, Beijing,  China.
FAU - Liu, Yaxin
AU  - Liu Y
AD  - Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical 
      University, Beijing,  China.
FAU - Qiao, Kexin
AU  - Qiao K
AD  - Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical 
      University, Beijing,  China.
FAU - Liu, Wen
AU  - Liu W
AD  - Department of Infectious Disease, Beijing Hospital of Traditional Chinese 
      Medicine, Capital Medical University, Beijing,  China.
FAU - Wang, Xianbo
AU  - Wang X
AD  - Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical 
      University, Beijing,  China.
LA  - eng
PT  - Journal Article
DEP - 20221220
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9807802
OTO - NOTNLM
OT  - hepatocellular carcinoma
OT  - mortality
OT  - prognosis
OT  - serum marker
OT  - soluble DR5
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/07 06:00
MHDA- 2023/01/07 06:01
PMCR- 2022/01/01
CRDT- 2023/01/06 02:34
PHST- 2022/09/09 00:00 [received]
PHST- 2022/12/02 00:00 [accepted]
PHST- 2023/01/06 02:34 [entrez]
PHST- 2023/01/07 06:00 [pubmed]
PHST- 2023/01/07 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.1040812 [doi]
PST - epublish
SO  - Front Oncol. 2022 Dec 20;12:1040812. doi: 10.3389/fonc.2022.1040812. eCollection 
      2022.